Tiago Marques sold $792 of KTTA
Chief Executive Officer at Pasithea Therapeutics Corp.. 960 shares at an average of $0.83, traded May 12, 2025, filed May 14, 2025.
Score components
- +25RoleCEO
- 0Trade size$792 at market
- 0Share of holdings soldSold 2.3% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -17.7%, 3m -24.8%, 6m -26.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-25-043621, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 12, 2025 | SOpen-market sale Common Stock | -960 | $0.83 | $792 | 40,001 | May 14, 2025 |
Related signals
Other insiders at Pasithea Therapeutics Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | KTTAbuy Pasithea Therapeutics Corp. | Coastlands Capital LP owner | $53k 100,000 shares | +3% | |
| 40Moderate | Pasithea Therapeutics Corp. | Simon Dumesnil director | $25k 33,333 shares | +1333% | |
| 50Moderate | Pasithea Therapeutics Corp. | Tiago Marques Chief Executive Officer | $25k 33,333 shares | +83% | |
| 50Moderate | Pasithea Therapeutics Corp. | Lawrence Steinman director | $100k 133,333 shares | +201% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.